Table 8.
Selected cell-based therapies against SARS-CoV-2 in clinical trials.
| Phase | Responsible party | Interventions | Recruitment status | Population (enrollment and age) | NCT number |
|---|---|---|---|---|---|
| 1, 2 | Beijing 302 Hospital | ● MSCs ● Saline containing 1% human serum albumin (solution of MSCs) |
Recruiting | 90 18–75 |
NCT04288102 |
| 1 | Beijing 302 Military Hospital | ● MSCs | Recruiting | 20 18–70 |
NCT04252118 |
| Not applicable | Puren Hospital Affiliated to Wuhan University of Science and Technology | ● UC-MSCs | Recruiting | – 18–75 |
NCT04293692 |
| Early 1 | CAR-T (Shanghai) Biotechnology Co., Ltd. | ● Dental pulp MSCs | Not yet recruiting | 24 18–75 |
NCT04302519 |
| 2 | Zhongnan Hospital | Biological: UC-MSCs | Recruiting | 10 18–75 |
NCT04269525 |
| 2 | Tianhe Stem Cell Biotechnologies Inc. | Combination product: stem cells and mononuclear cells isolated by apheresis | Not yet recruiting | 20 18–60 |
NCT04299152 |
| 1 | Ruijin Hospital | ● MSCs-derived exosomes | Not yet recruiting | 30 18–75 |
NCT04276987 |
| 1 | Azidus Brasil | ● NestCell® | Not yet recruiting | 66 ≤18 |
NCT04315987 |
| Not applicable | Wuhan Union Hospital | ● UC-MSCs | Not yet recruiting | 48 18–60 |
NCT04273646 |
| 1, 2 | Chongqing Public Health Medical Center | ● NK cells, IL15-NK cells, NKG2D CAR-NK cells, ACE2 CAR-NK cells and NKG2D-ACE2 CAR-NK cells | Recruiting | 90 ≤18 |
NCT04324996 |
| 1 | Stem Cells Arabia | ● WJ-MSCs | Recruiting | 5 ≤18 |
NCT04313322 |
| 1 | Xinxiang medical university | ● NK cells | Recruiting | 30 18–65 |
NCT04280224 |